Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Leukemia. 2014 Jun 20;29(2):346–355. doi: 10.1038/leu.2014.199

Figure 4.

Figure 4

Immunonanoparticle 2A2-ILPs targeting ROR1+ CLL cells for OSU-2S drug delivery. (a) Internalization curve for 2A2-IgG bound ROR1 in CLL cells. Internalization involving time-dependent increase in mean fluorescent intensity (MFI) of labeled antibody on CLL cells treated with 2A2-IgG, αCD19 or αCD37 is shown. Bars represent mean ± SD, P<0.001 (N=7). (b) Internalization of 2A2-ILP. MFI showing the binding and uptake of 2A2-ILP calcein by CLL cells, normal B cells and T cells (N=8, P<0.0001). (c-d) 2A2-OSU-2S-ILP mediates specific cytotoxicity in CLL cells. 1×106 normal B cells from healthy donors or CLL cells were incubated with different formulation at 5µM of OSU-2S and 0.1µg/ml mAbs for 24hr before viability was analyzed by flow cytometry (mean ± SEM). (c) No difference in cytotoxicity between 2A2-OSU-2S-ILP and IgG-OSU-2S-ILP formulations was found for normal B cells (N=4). (d) 2A2-OSU-2S-ILP significantly induced improved cytotoxicity in CLL cells compared to non-targeting IgG-OSU-2S-ILP (N=8, P<0.01).